BioSpace News Archive

Pharming Group N.V. presents its (unaudited) interim financial report for the first nine months and the third quarter ended 30 September 2018.

Initial data from the first cohort expected in first half of 2019

Shares of South San Francisco-based Achaogen, Inc. fell more than 12 percent in Monday trading after the company signaled that it began a review of strategic alternatives that could include a sale of the company.

Lilly is paying NextCure $25 million upfront. NextCure will be eligible for various development and commercial milestone payments, as well as royalties on any commercial products. In addition, Lilly invested $15 million in NextCure equity.

Some life science professionals might not think it’s a big deal if a co-worker constantly interrupts them. However, if you are not effectively communicating your thoughts, ideas, and solutions to problems it’s harder for you to be noticed as a key contributor on your team.

Cambridge, Mass.-based AVEO Oncology hit the mark in its Phase III study of a treatment for highly refractory advanced or metastatic renal cell carcinoma (RCC). The company said its drug tivozanib met its primary endpoint of demonstrating a statistically significant benefit in progression-free survival (PFS).

AstraZeneca is unloading rights to Alvesco (ciclesonide) to treat persistent asthma, and Omnaris and Zetonna (ciclesonide) to treat nasal symptoms associated with rhinitis. The company indicates that the rights cover markets outside the United States and the U.S. royalties for the drugs.

Nektar Therapeutics, based in San Francisco, and New York-based Pfizer are teaming up to evaluate combination regimens in several cancer settings. Those include metastatic castration-resistant prostate cancer (mCRPC) and squamous cell carcinoma of the head and heck (SCCHN).

These nondilutive funds support development, testing and IND submission of the Company’s pediatric esophageal implant candidate

Results in normal healthy volunteers provide safety, pharmacokinetic and pharmacodynamic data